NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on March 26, 2014. The Company will continue to trade under the symbol “ATNM” but will withdraw its shares from listing on the OTCQB concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.
Help employers find you! Check out all the jobs and post your resume.
